Samuel R Denmeade

Professor

1985 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2019

An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response

Rogers, O., Yen, H., Solomon, A., Drake, C. & Denmeade, S. R., Jul 1 2019, In : Prostate. 79, 10, p. 1071-1078 8 p.

Research output: Contribution to journalArticle

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Kapoor, R., Deek, M. P., McIntyre, R., Raman, N., Kummerlowe, M., Chen, I., Gaver, M., Wang, H., Denmeade, S., Lotan, T., Paller, C., Markowski, M., Carducci, M., Eisenberger, M., Beer, T. M., Song, D. Y., Deweese, T. L., Hearn, J. W., Greco, S., Deville, C. & 7 others, Desai, N. B., Heath, E. I., Liauw, S., Spratt, D. E., Hung, A. Y., Antonarakis, E. S. & Tran, P. T., Jun 13 2019, In : BMC cancer. 19, 1, 572.

Research output: Contribution to journalArticle

Open Access

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma

Hahn, A. W., Drake, C., Denmeade, S. R., Zakharia, Y., Maughan, B. L., Kennedy, E., Link, C., Vahanian, N., Hammers, H. & Agarwal, N., Jan 1 2019, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

Open Access
Open Access

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer

Paller, C., Piana, D., Eshleman, J., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S., Pomper, M. G., Antonarakis, E., Luo, J. & Eisenberger, M., Jan 1 2019, In : Prostate. 79, 14, p. 1597-1603 7 p.

Research output: Contribution to journalArticle

Open Access

Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage

Chatterjee, P., Schweizer, M. T., Lucas, J. M., Coleman, I., Nyquist, M. D., Frank, S. B., Tharakan, R., Mostaghel, E., Luo, J., Pritchard, C. C., Lam, H. M., Corey, E., Antonarakis, E. S., Denmeade, S. R. & Nelson, P. S., Jul 16 2019, In : The Journal of clinical investigation. 130

Research output: Contribution to journalArticle

Open Access
2018

Bipolar androgen therapy in the treatment of prostate cancer

Denmeade, S. R., Jun 1 2018, In : Clinical Advances in Hematology and Oncology. 16, 6, p. 408-411 4 p.

Research output: Contribution to journalComment/debate

Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise

Krueger, T. E. G., Thorek, D. L. J., Denmeade, S. R., Isaacs, J. T. & Brennen, W., Sep 1 2018, In : Stem cells translational medicine. 7, 9, p. 651-663 13 p.

Research output: Contribution to journalReview article

Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial

Paller, C., Zhou, X. C., Heath, E. I., Taplin, M. E., Mayer, T., Stein, M. N., Bubley, G. J., Pili, R., Hudson, T., Kakarla, R., Abbas, M. M., Anders, N., Dowling, D., King, S., Bruns, A. B., Wagner, W. D., Drake, C. G., Antonarakis, E., Eisenberger, M., Denmeade, S. R. & 3 others, Rudek-Renaut, M., Rosner, G. & Carducci, M. A., Jan 15 2018, In : Clinical Cancer Research. 24, 2, p. 306-315 10 p.

Research output: Contribution to journalArticle

PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer

Rogers, O. C., Anthony, L., Rosen, D. M., Brennen, W. & Denmeade, S. R., Apr 27 2018, In : Oncotarget. 9, 32, p. 22436-22450 15 p.

Research output: Contribution to journalArticle

2017

Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay

Ajiboye, A. S., Esopi, D., Yegnasubramanian, S. & Denmeade, S. R., Jun 1 2017, In : Prostate. 77, 8, p. 829-837 9 p.

Research output: Contribution to journalArticle

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

Schweizer, M. T., Antonarakis, E. & Denmeade, S. R., 2017, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: An open-label, phase 2, multicohort study

Teply, B. A., Wang, H., Luber, B., Sullivan, R., Rifkind, I., Bruns, A., Spitz, A., DeCarli, M., Sinibaldi, V., Pratz, C. F., Lu, C., Silberstein, J. L., Luo, J., Schweizer, M. T., Drake, C. G., Carducci, M. A., Paller, C., Antonarakis, E., Eisenberger, M. & Denmeade, S. R., Jan 1 2017, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Detection fidelity of AR mutations in plasma derived cell-free DNA

Goldstein, A., Toro, P. V., Lee, J., Silberstein, J. L., Nakazawa, M., Waters, I., Cravero, K., Chu, D., Cochran, R. L., Kim, M., Shinn, D., Torquato, S., Hughes, R. M., Pallavajjalla, A., Carducci, M. A., Paller, C., Denmeade, S. R., Kressel, B., Trock, B., Eisenberger, M. & 3 others, Antonarakis, E., Park, B. H. & Hurley, P., 2017, In : Oncotarget. 8, 9, p. 15651-15662 12 p.

Research output: Contribution to journalArticle

Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate

Brennen, W., Zhang, B., Kulac, I., Kisteman, L. N., Antony, L., Wang, H., Meeker, A. K., Demarzo, A. M., Garraway, I. P., Denmeade, S. R. & Isaacs, J. T., 2017, In : Oncotarget. 8, 29, p. 46710-46727 18 p.

Research output: Contribution to journalArticle

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer

Isaacs, J. T., Brennen, W. & Denmeade, S. R., Aug 24 2017, (Accepted/In press) In : Cell Cycle. p. 1-2 2 p.

Research output: Contribution to journalArticle

2016

A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer

Levy, O., Brennen, W., Han, E., Rosen, D. M., Musabeyezu, J., Safaee, H., Ranganath, S., Ngai, J., Heinelt, M., Milton, Y., Wang, H., Bhagchandani, S. H., Joshi, N., Bhowmick, N., Denmeade, S. R., Isaacs, J. T. & Karp, J. M., Jun 1 2016, In : Biomaterials. 91, p. 140-150 11 p.

Research output: Contribution to journalArticle

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study

Schweizer, M. T., Wang, H., Luber, B., Nadal, R., Spitz, A., Rosen, D. M., Cao, H., Antonarakis, E., Eisenberger, M., Carducci, M. A., Paller, C. & Denmeade, S. R., Sep 15 2016, In : Prostate. 76, 13, p. 1218-1226 9 p.

Research output: Contribution to journalArticle

Clinical Applications of Molecular Imaging in the Management of Prostate Cancer

Gorin, M., Rowe, S. & Denmeade, S. R., 2016, (Accepted/In press) In : PET Clinics.

Research output: Contribution to journalArticle

Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer

Teply, B. A., Kachhap, S., Eisenberger, M. & Denmeade, S. R., 2016, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death

Na, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., Gulukota, K., Helseth, D. L., Quinn, M., Humphries, E., Wiley, K. E., Isaacs, S. D., Wu, Y., Liu, X., Zhang, N., Wang, C. H. & 17 others, Khandekar, J., Hulick, P. J., Shevrin, D. H., Cooney, K. A., Shen, Z., Partin, A. W., Carter, H. B., Carducci, M. A., Eisenberger, M., Denmeade, S. R., McGuire, M., Walsh, P., Helfand, B. T., Brendler, C. B., Ding, Q., Xu, J. & Isaacs, W. B., 2016, (Accepted/In press) In : European Urology.

Research output: Contribution to journalArticle

Mipsagargin, a novel thapsigargin-based PSMA-Activated prodrug: Results of a first-in-man phase i clinical trial in patients with refractory, advanced or metastatic solid tumours

Mahalingam, D., Wilding, G., Denmeade, S. R., Sarantopoulas, J., Cosgrove, D., Cetnar, J., Azad, N., Bruce, J., Kurman, M., Allgood, V. E. & Carducci, M. A., Apr 26 2016, In : British Journal of Cancer. 114, 9, p. 986-994 9 p.

Research output: Contribution to journalArticle

Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA Zymogen

Sangster-Guity, N., Tu-Sekine, B., Raben, D. M., Denmeade, S. R. & Williams, S. A., Sep 15 2016, In : Prostate. 76, 13, p. 1203-1217 15 p.

Research output: Contribution to journalArticle

2015

A phase i study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination

Paller, C., Rudek-Renaut, M., Zhou, X. C., Wagner, W. D., Hudson, T. S., Anders, N., Hammers, H. J., Dowling, D., King, S., Antonarakis, E., Drake, C. G., Eisenberger, M., Denmeade, S. R., Rosner, G. & Carducci, M. A., Oct 1 2015, In : Prostate. 75, 14, p. 1518-1525 8 p.

Research output: Contribution to journalArticle

CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells

Barakat, D. J., Zhang, J., Barberi, T., Denmeade, S. R., Friedman, A. D. & Paz-Priel, I., Nov 26 2015, In : Oncogene. 34, 48, p. 5912-5922 11 p.

Research output: Contribution to journalArticle

Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines

Akinboye, E., Bamji, Z. D., Kwabi-Addo, B., Ejeh, D., Copeland, R. L., Denmeade, S. R. & Bakare, O., Sep 1 2015, In : Bioorganic and Medicinal Chemistry. 23, 17, p. 5839-5845 7 p.

Research output: Contribution to journalArticle

Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer

LeBeau, A. M. & Denmeade, S. R., Mar 1 2015, In : Molecular Cancer Therapeutics. 14, 3, p. 659-668 10 p.

Research output: Contribution to journalArticle

Targeting thapsigargin towards tumors

Doan, N. T. Q., Paulsen, E. S., Sehgal, P., Møller, J. V., Nissen, P., Denmeade, S. R., Isaacs, J. T., Dionne, C. A. & Christensen, S. B., 2015, In : Steroids. 97, p. 2-7 6 p.

Research output: Contribution to journalArticle

2014

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Antonarakis, E., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., Lotan, T., Zheng, Q., Demarzo, A. M., Isaacs, J. T., Isaacs, W. B., Nadal, R., Paller, C., Denmeade, S. R., Carducci, M. A., Eisenberger, M. & 1 others, Luo, J., Sep 11 2014, In : New England Journal of Medicine. 371, 11, p. 1028-1038 11 p.

Research output: Contribution to journalArticle

Clinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

Nadal, R., Zhang, Z., Rahman, H., Schweizer, M. T., Denmeade, S. R., Paller, C., Carducci, M. A., Eisenberger, M. & Antonarakis, E., Nov 1 2014, In : Prostate. 74, 15, p. 1560-1568 9 p.

Research output: Contribution to journalArticle

Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-Activated prodrug in murine xenograft models of human cancer

Brennen, W., Rosen, D. M., Chaux, A., Netto, G. J., Isaacs, J. T. & Denmeade, S. R., 2014, In : Prostate. 74, 13, p. 1308-1319 12 p.

Research output: Contribution to journalArticle

2013

Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia

Elhilali, M. M., Pommerville, P., Yocum, R. C., Merchant, R., Roehrborn, C. G. & Denmeade, S. R., Apr 2013, In : Journal of Urology. 189, 4, p. 1421-1426 6 p.

Research output: Contribution to journalArticle